Please refer attachment
Awaiting price reaction for this filing.
Piramal Pharma reported FY25 consolidated revenue of ₹9,151 Cr, up 12% YoY, crossing the $1 Bn milestone. EBITDA grew 15% to ₹1,580 Cr with margin steady at 17%, while net profit after tax (after exceptional) surged 411% to ₹91 Cr. Q4FY25 revenue rose 8% YoY to ₹2,754 Cr with EBITDA at ₹603 Cr (22% margin) and PAT up 52% to ₹154 Cr. The CDMO segment led growth at 15% YoY (₹5,447 Cr), driven by a 50%+ jump in on-patent commercial manufacturing revenues to $179 mn and innovation work rising to 54% of CDMO mix. CHG grew 8% (₹2,633 Cr) with some margin moderation due to India capacity expansion, expected to recover from FY26. ICH crossed ₹1,000 Cr with 20% growth in power brands. Net Debt/EBITDA improved sharply from 5.6x (FY23) to 2.7x.
Strong delivery against annual guidance ($1 Bn revenue, 17% EBITDA margin, sub-3x leverage) and clear FY2030 targets ($2+ Bn revenue, 25% EBITDA margin, ~1x leverage) signal steady execution. Improving leverage profile and CDMO innovation mix expansion are positive for shareholders, though CHG margin recovery remains a key thing to watch in FY26.